Rein Therapeutics (RNTX) Cash from Operations (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Cash from Operations of 3424000.0 for Q1 2026, up 44.55% year-over-year from 2368720.59 in Q1 2025, and down 6.34% quarter-over-quarter from 3220000.0 in Q4 2025.
Rein Therapeutics (RNTX) Cash from Operations (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Cash from Operations for 11 consecutive years, with 3424000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 44.55% year-over-year to 3424000.0; the TTM figure through Mar 2026 stood at 16610000.0 (up 28.39% YoY), while the FY2025 annual figure was 19361000.0, up 13.14% from the prior year.
- Cash from Operations slipped to 3424000.0 in Q1 2026 per RNTX's latest filing, from 3220000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1640000.0 in Q3 2023 and bottomed at 10391000.0 in Q4 2023.
- Historically, Cash from Operations has averaged 5279352.94 across 5 years, with a median of 4812000.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Operations surged 76.47% — and 2024, when it sank 169.22%.
- Rein Therapeutics' Cash from Operations stood at 4409000.0 in 2022, then slumped by 135.68% to 10391000.0 in 2023, then soared by 53.69% to 4812000.0 in 2024, then soared by 33.08% to 3220000.0 in 2025, then slipped by 6.34% to 3424000.0 in 2026.
- Business Quant data shows RNTX's Cash from Operations at 3424000.0 in Q1 2026, 3220000.0 in Q4 2025, and 3548000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | -8.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.64 Mn |
| Jun 30, 2026 | -8.64 Mn |
| Mar 31, 2026 | -3.42 Mn |
| Mar 31, 2026 | -3.42 Mn |
| Dec 31, 2025 | -3.22 Mn |
| Dec 31, 2025 | -3.22 Mn |
| Sep 30, 2025 | -3.55 Mn |
| Sep 30, 2025 | -3.55 Mn |
| Jun 30, 2025 | -6.42 Mn |
| Jun 30, 2025 | -6.42 Mn |
| Mar 31, 2025 | -6.18 Mn |
| Mar 31, 2025 | -6.18 Mn |
| Dec 31, 2024 | -4.81 Mn |
| Dec 31, 2024 | -4.81 Mn |
| Sep 30, 2024 | -3.82 Mn |
| Sep 30, 2024 | -3.82 Mn |
| Jun 30, 2024 | -8.39 Mn |
| Jun 30, 2024 | -8.39 Mn |
| Mar 31, 2024 | -5.27 Mn |
| Mar 31, 2024 | -5.27 Mn |